# A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

> **NCT01839526** · PHASE1 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 39 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Iohexol

## Key facts

- **NCT ID:** NCT01839526
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Enrollment period not extended and screening stopped for slow recruitment and in accordance with provisions of the protocol. Not linked to any safety concern
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839526, "A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01839526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*